Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
Compugen (NASDAQ: CGEN) has announced the enhancement of its AI/ML predictive computational discovery platform, Unigen™, through collaboration with Ultima Genomics' single cell sequencing technology. The partnership combines Compugen's platform with Ultima's UG 100™ sequencing platform to gain deeper insights into tumor biology and immune regulation.
Key findings presented at the AGBT 2025 General Meeting revealed high consistency in single-cell expression levels between Ultima's UG 100 and Illumina's Novaseq 6000 platforms. The UG 100 demonstrated superior capability in identifying 3' mRNA transcript endings, potentially advancing the understanding of gene structure in tumor biology.
The collaboration aims to leverage Ultima's technology for developing proprietary single cell atlases to accelerate new immunotherapy discoveries. The research findings contribute to Unigen's predictive models, with potential applications in developing new cancer immunotherapies.
Compugen (NASDAQ: CGEN) ha annunciato il potenziamento della sua piattaforma di scoperta computazionale predittiva AI/ML, Unigen™, attraverso una collaborazione con la tecnologia di sequenziamento a cellula singola di Ultima Genomics. Questa partnership combina la piattaforma di Compugen con la piattaforma di sequenziamento UG 100™ di Ultima per ottenere approfondimenti più profondi sulla biologia dei tumori e sulla regolazione immunitaria.
I risultati chiave presentati durante il Meeting Generale AGBT 2025 hanno rivelato un'elevata coerenza nei livelli di espressione a cellula singola tra UG 100 di Ultima e la piattaforma Novaseq 6000 di Illumina. L'UG 100 ha dimostrato una capacità superiore nell'identificare le estremità dei trascritti mRNA 3', potenzialmente avanzando la comprensione della struttura genica nella biologia tumorale.
La collaborazione mira a sfruttare la tecnologia di Ultima per sviluppare atlanti a cellula singola proprietari, accelerando così le nuove scoperte nel campo dell'immunoterapia. I risultati della ricerca contribuiscono ai modelli predittivi di Unigen, con potenziali applicazioni nello sviluppo di nuove immunoterapie per il cancro.
Compugen (NASDAQ: CGEN) ha anunciado la mejora de su plataforma de descubrimiento computacional predictivo AI/ML, Unigen™, a través de una colaboración con la tecnología de secuenciación de célula única de Ultima Genomics. La asociación combina la plataforma de Compugen con la plataforma de secuenciación UG 100™ de Ultima para obtener una comprensión más profunda de la biología tumoral y la regulación inmunitaria.
Los hallazgos clave presentados en la Reunión General AGBT 2025 revelaron una alta consistencia en los niveles de expresión de célula única entre UG 100 de Ultima y la plataforma Novaseq 6000 de Illumina. El UG 100 demostró una capacidad superior para identificar los extremos de los transcritos de mRNA 3', lo que podría avanzar en la comprensión de la estructura genética en la biología tumoral.
La colaboración tiene como objetivo aprovechar la tecnología de Ultima para desarrollar atlas de células únicas propietarios, acelerando así los nuevos descubrimientos en inmunoterapia. Los hallazgos de la investigación contribuyen a los modelos predictivos de Unigen, con aplicaciones potenciales en el desarrollo de nuevas inmunoterapias contra el cáncer.
Compugen (NASDAQ: CGEN)은 Ultima Genomics의 단일 세포 시퀀싱 기술과 협력하여 AI/ML 예측 컴퓨터 발견 플랫폼인 Unigen™을 향상시켰다고 발표했습니다. 이 파트너십은 Compugen의 플랫폼과 Ultima의 UG 100™ 시퀀싱 플랫폼을 결합하여 종양 생물학과 면역 조절에 대한 더 깊은 통찰력을 얻는 것을 목표로 합니다.
AGBT 2025 일반 회의에서 발표된 주요 결과는 Ultima의 UG 100과 Illumina의 Novaseq 6000 플랫폼 간의 단일 세포 발현 수준에서 높은 일관성을 보여주었습니다. UG 100은 3' mRNA 전사체 말단을 식별하는 데 뛰어난 능력을 보여주어 종양 생물학에서 유전자 구조에 대한 이해를 발전시킬 수 있는 가능성을 제공합니다.
이 협력은 Ultima의 기술을 활용하여 독점 단일 세포 아틀라스를 개발하고 새로운 면역 요법 발견을 가속화하는 것을 목표로 합니다. 연구 결과는 Unigen의 예측 모델에 기여하며, 새로운 암 면역 요법 개발에 잠재적인 응용 프로그램을 제공합니다.
Compugen (NASDAQ: CGEN) a annoncé l'amélioration de sa plateforme de découverte computationnelle prédictive AI/ML, Unigen™, grâce à une collaboration avec la technologie de séquençage de cellule unique d'Ultima Genomics. Ce partenariat combine la plateforme de Compugen avec la plateforme de séquençage UG 100™ d'Ultima pour obtenir des aperçus plus profonds sur la biologie tumorale et la régulation immunitaire.
Les résultats clés présentés lors de la Réunion Générale AGBT 2025 ont révélé une grande cohérence dans les niveaux d'expression à cellule unique entre UG 100 d'Ultima et la plateforme Novaseq 6000 d'Illumina. L'UG 100 a démontré une capacité supérieure à identifier les extrémités des transcrits d'ARNm 3', ce qui pourrait faire progresser la compréhension de la structure génique dans la biologie tumorale.
La collaboration vise à tirer parti de la technologie d'Ultima pour développer des atlas de cellules uniques propriétaires afin d'accélérer les nouvelles découvertes en immunothérapie. Les résultats de la recherche contribuent aux modèles prédictifs d'Unigen, avec des applications potentielles dans le développement de nouvelles immunothérapies contre le cancer.
Compugen (NASDAQ: CGEN) hat die Verbesserung seiner AI/ML-prädiktiven computergestützten Entdeckungsplattform Unigen™ durch eine Zusammenarbeit mit der Einzelzell-Sequenzierungstechnologie von Ultima Genomics bekannt gegeben. Die Partnerschaft kombiniert die Plattform von Compugen mit Ultimas UG 100™-Sequenzierungsplattform, um tiefere Einblicke in die Tumorbiologie und Immunregulation zu gewinnen.
Wichtige Ergebnisse, die auf dem AGBT 2025 General Meeting präsentiert wurden, zeigten eine hohe Konsistenz der Einzelzell-Expressionsniveaus zwischen Ultimas UG 100 und Illuminas Novaseq 6000-Plattformen. Die UG 100 zeigte eine überlegene Fähigkeit zur Identifizierung von 3' mRNA-Transkriptenden, was potenziell das Verständnis der Genstruktur in der Tumorbiologie vorantreiben könnte.
Die Zusammenarbeit zielt darauf ab, Ultimas Technologie zu nutzen, um proprietäre Einzelzell-Atlanten zu entwickeln und neue Entdeckungen in der Immuntherapie zu beschleunigen. Die Forschungsergebnisse tragen zu Unigens prädiktiven Modellen bei, mit potenziellen Anwendungen in der Entwicklung neuer Krebsimmuntherapien.
- Enhanced AI/ML platform capabilities through integration with advanced sequencing technology
- Successful validation of platform consistency with existing industry standard (Novaseq 6000)
- Improved ability to study gene structure and immune regulation
- None.
Insights
Compugen's integration of Ultima Genomics' single-cell sequencing technology with their AI-powered Unigen™ platform represents a strategic enhancement of their computational target discovery capabilities. This collaboration addresses a critical bottleneck in cancer immunotherapy development: the ability to precisely identify novel immune regulatory mechanisms at the cellular level.
The technology integration offers three key advantages for Compugen's drug discovery pipeline:
- More accurate identification of gene structure and splicing patterns specific to tumor microenvironments
- Enhanced ability to detect subtle regulatory mechanisms that may reveal new immunotherapy targets
- Potential acceleration of target validation through improved single-cell resolution data
While technologically impressive, investors should note that this represents an early-stage research tool enhancement rather than an immediate clinical catalyst. The value proposition lies in Compugen potentially identifying novel immunotherapy targets that competitors might miss using conventional sequencing approaches.
For context, Compugen's business model relies on computational discovery of immune checkpoints, with partnerships and licensing agreements providing revenue streams. This technology could strengthen their position in partnership negotiations by demonstrating superior target identification capabilities.
The collaboration with Ultima Genomics aligns with industry trends toward integrating advanced sequencing with AI/ML for drug discovery, but meaningful financial impact would likely materialize only if it leads to new validated targets entering the development pipeline in the coming 12-24 months.
- Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology and immune regulation
- Leveraging Compugen's computational analytical tools uncovered high consistency in single-cell expression levels across Ultima's UG 100 sequencing platform, offering a potential advantage for demarcation of transcript termination.
- Research presented at Advances in Genome Biology and Technology (AGBT) 2025 General Meeting
HOLON,
"We are excited to collaborate with Ultima Genomics, a pioneer in next generation gene sequencing, to enhance our proprietary gene sequencing database, which is part of our Unigen platform," said Eran Ophir, Ph.D., Chief Scientific Officer at Compugen. "We developed algorithms to study gene splicing in single cell resolution and applied it to analyze patient tumor samples to uncover new potential regulatory mechanisms in immuno-oncology. Some of the findings were presented at the AGBT conference. Compugen plans to further harness Ultima's technology to develop its proprietary single cell atlases for accelerated discovery of new immunotherapies."
"We are excited to support Compugen's capabilities in predictive computational discovery of new drug targets and development of new cancer immunotherapies," said Gilad Almogy, Founder and CEO of Ultima Genomics. "We built our innovative sequencing architecture and our UG 100 sequencing platform to enable researchers to unlock new applications and insights through lower cost sequencing and more omics data. The successful outcome of our collaboration with Compugen is a great example of an application that is data-starved due to the constraints of conventional sequencing technology and can be transformed through large scale data and AI/ML techniques. Single cell sequencing is also an excellent fit for our technology which is now compatible with the leading library prep technologies."
Dr. Roy Granit, Head of Computational Discovery at Compugen is the lead author on a poster presented by Ultima Genomics at the Advances in Genome Biology and Technology (AGBT) 2025 general meeting on February 25, 2025, in Marco Island, Florida.
Poster presentation details:
Title: Using 3' Single Cell Sequencing to Study Patient-Derived Tumor Cells Reveals Enhanced Potential to Study Differential Splicing at the Cell Type Level
Poster number: 224
Date and time: Tuesday, February 25, 4:45 p.m. - 6:10 p.m. ET
Leading author: Roy Granit, Ph.D., Director, Head of Computational Discovery, Compugen,
Presenter: Zohar Shipony, Ph.D. Ultima Genomics,
Key Findings:
- Comparative analysis using tumor samples from cancer patients, found high consistency in single-cell expression levels across Ultima Genomics' UG 100 and Illumina's Novaseq 6000 sequencing platforms.
- UG 100 offers clearer demarcation of 3' mRNA transcript end and provides a unique opportunity to study gene structure, which can potentially be harnessed to better understand tumor biology and immune regulation.
- Gene structure information identified in this approach is contributing to the predictive models of Unigen.
The poster is available on the publications section of Compugen's website, www.cgen.com.
About Unigen™
Compugen has been at the forefront of decoding cancer biology, with its AI/ML powered predictive computational discovery platform, recently branded as Unigen™. Unigen is Compugen's code-to-cure, flexible-loop platform for the computational prediction of novel drug target discovery and development of cancer immunotherapy. Unigen combines Compugen's deep scientific knowledge, AI/ML predictive algorithms and a cloud-based, technology-agnostic platform integrating a variety of biological data such as multi-omics, single-cell RNA sequencing and spatial omics data. The outcomes from Compugen's preclinical and clinical trials enrich the proprietary knowledgebase to discover additional novel drug targets and further understand complex biology. To date, Unigen has yielded multiple novel immuno-oncology drug targets, potential first- or best-in-class clinical stage immuno-oncology programs, validating partnerships with multiple pharmaceutical companies and undisclosed programs in its early-stage pipeline.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Compugen is headquartered in
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statement regarding Ultima's UG 100™ sequencing platform offering a potential advantage for demarcation of transcript termination and statements regarding Compugen's plans to further harness Ultima's technology to develop its proprietary single cell atlases for accelerated discovery of new immunotherapies. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: the clinical trials of any product candidates that Compugen, or any current or future collaborators, may develop may fail to satisfactorily demonstrate safety and efficacy to the FDA, and Compugen, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates; Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen's approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; general market, political and economic conditions in the countries in which Compugen operates, including
Compugen contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-enhances-its-aiml-predictive-computational-discovery-platform-unigen-with-ultima-genomics-single-cell-genomics-sequencing-technology-302385891.html
SOURCE Compugen Ltd.
FAQ
What are the key findings from Compugen's (CGEN) collaboration with Ultima Genomics in 2025?
How will the Unigen platform enhancement affect Compugen's (CGEN) cancer research capabilities?
What was presented at the AGBT 2025 conference regarding CGEN's research?
How does Ultima's UG 100 technology benefit Compugen's (CGEN) research platform?
